- 1 Full Title: Colocalization of expression transcripts with COVID-19 outcomes is rare across cell states, cell types
- 2 and organs.
- 3 Short Title: Factors influencing colocalization of gene expression with COVID-19 outcomes.
- 4 Authors: Julian Daniel Sunday Willett^{1,2,3}, Tianyuan Lu^{1,2,3}, Tomoko Nakanishi^{1,2,4,5,6}, Satoshi Yoshiji^{1,2,4,5,6},
- 5 Guillaume Butler-Laporte¹, Sirui Zhou^{1,2}, Yossi Farjoun¹, J. Brent Richards^{1,2,8,9,10}
- 6

7 Corresponding author:

- 8 Brent Richards
- 9 <u>brent.richards@mcgill.ca</u>
- 10 Pavillon H-413, Jewish General Hospital
- 11 3755 Cote Ste Catherine
- 12 Montreal, QC, Canada, H3T 1E2
- 13

14 Affiliations:

- 15 1. Centre for Clinical Epidemiology, Department of Medicine, Lady Davis Institute, Jewish General Hospital,
- 16 McGill University, Montréal, Québec, Canada.
- 17 2. McGill University, Montreal, Quebec, Canada
- 18 3. Quantitative Life Sciences Program, McGill University, Montreal, Quebec, Canada
- 19 4. Department of Human Genetics, McGill University, Montreal, Quebec, Canada
- 5. Kyoto-McGill International Collaborative Program in Genomic Medicine, Graduate School of Medicine,
 Kyoto University, Kyoto, Japan
- 22 6. Research Fellow, Japan Society for the Promotion of Science, Tokyo, Japan.
- 23 7. Genome Centre, McGill University, Montreal, Quebec, Canada
- Departments of Medicine, Human Genetics, Epidemiology and Biostatistics, McGill University, Montréal,
 Ouebec, Canada
- 26 9. Department of Twin Research, King's College London, London, United Kingdom
- 27 10. Five Prime Sciences Inc, Montréal, Québec, Canada

28

Colocalization of expression transcripts with COVID-19 outcomes is dependent on cell-type and cell-state.

29 Abstract:

30 Identifying causal genes at GWAS loci can help pinpoint targets for therapeutic interventions. Expression 31 studies can disentangle such loci but signals from expression quantitative trait loci (eQTLs) often fail to 32 colocalize—which means that the genetic control of measured expression is not shared with the genetic control of 33 disease risk. This may be because gene expression is measured in the wrong cell type, physiological state, or organ. 34 We tested whether Mendelian randomization (MR) could identify genes at loci influencing COVID-19 outcomes 35 and whether the colocalization of genetic control of expression and COVID-19 outcomes was influenced by cell 36 type, cell stimulation, and organ. 37 We conducted MR of *cis*-eQTLs from single cell (scRNA-seq) and bulk RNA sequencing. We then tested 38 variables that could influence colocalization, including cell type, cell stimulation, RNA sequencing modality, organ, 39 symptoms of COVID-19, and SARS-CoV-2 status among individuals with symptoms of COVID-19. The outcomes 40 used to test colocalization were COVID-19 severity and susceptibility as assessed in the Host Genetics Initiative 41 release 7. 42 Most transcripts identified using MR did not colocalize when tested across cell types, cell state and in 43 different organs. Most that did colocalize likely represented false positives due to linkage disequilibrium. In general, 44 colocalization was highly variable and at times inconsistent for the same transcript across cell type, cell stimulation 45 and organ. While we identified factors that influenced colocalization for select transcripts, identifying 33 that 46 mediate COVID-19 outcomes, our study suggests that colocalization of expression with COVID-19 outcomes is 47 partially due to noisy signals even after following quality control and sensitivity testing. These findings illustrate the 48 present difficulty of linking expression transcripts to disease outcomes and the need for skepticism when observing 49 eQTL MR results, even accounting for cell types, stimulation state and different organs. 50 51 Author Summary: The genetic determinants of disease and gene expression often do not colocalize (which means 52 they do not share a single causal signal). While some researchers have identified factors that could explain this 53 disconnect, such as immune stimulation or tissue studied, understanding of this complex phenomenon remains

54 incomplete. A deeper understanding could help identify additional genes that mediate disease, affording promising

- targets for treatment or prevention of disease. We used RNA sequencing data collected at the single cell and bulk
- tissue level to identify genes whose expression influenced COVID-19 outcomes. We assessed which variables

- 57 influencing colocalization, including cell type, cell stimulation, RNA sequencing modality, organ, symptoms of
- 58 COVID-19, and SARS-CoV-2 status among individuals with symptoms of COVID-19. We observed that
- 59 colocalization of specific candidate genes identified by MR was highly variable and influenced by multiple factors,
- 60 including cell state and cell population. These results illustrate that even after assessing multiple variables that may
- 61 influence colocalization, there existed few examples of genes identified by MR that colocalized with gene
- 62 expression. Future studies would benefit from larger transcriptomics study cohorts and more advanced statistical
- 63 methods which better account for differences in linkage disequilibrium panels between data sources.
- 64
- 65 Keywords: COVID-19, colocalization, Mendelian randomization, eQTL, scRNA

Colocalization of expression transcripts with COVID-19 outcomes is dependent on cell-type and cell-state.

66 Introduction:

67 Severe COVID-19 is partially influenced by immune hyperstimulation (Merad et al. 2022; Tan et al. 2021).
68 The immune response is mediated by different immune cell subtypes, acting at varying time points during infection
69 across tissues (Ong et al. 2020; Tan et al. 2021). Understanding the dynamics of this process may pinpoint targets
70 helpful for COVID-19 interventions, as previously shown (De Biasi et al. 2020; Kundu et al. 2022; Mathew et al.
71 2020).

72 One way to investigate mechanisms influencing COVID-19 outcomes is to determine the underlying 73 contributory genetic factors. GWAS has identified 87 loci associated with COVID-19 outcomes, but it is often 74 unclear which gene(s) at such loci drive this association (Covid-19 Host Genetics Initiative 2021). Resolving a 75 GWAS locus to its causal gene(s) is non-trivial (Forgetta et al. 2022). One way to identify causal genes at GWAS 76 loci is to examine whether associated SNPs influence outcomes in an appropriate cell type. However, genetic 77 determinants of gene expression (expression quantitative trait loci; eQTL) have often failed to "colocalize" with 78 disease outcomes (Connally et al. 2022). Colocalization, in this context, means that gene expression and the disease 79 outcome share a single common causal SNP (Connally et al. 2022). This lack of colocalization is concerning and not 80 fully resolved. However, given the central importance of gene expression in disease incidence and progression, 81 efforts are required to explain the paradox that the genetic determinants of gene expression often appear different 82 than the those of disease, even for known causal genes in known causal cell types or tissues (Connally et al. 2022). 83 We sought to determine if this lack of colocalization could be explained when cell type, cell stimulation, method of 84 sequencing and organ were taken into account.

85 One factor that may influence colocalization is the population of cells studied. Gene expression is typically 86 determined in bulk tissue, which provides a mixture of cells from the tissue. Such signal dilution, combined with 87 complex factors such as cell-cell interactions, may explain why bulk tissue eQTLs often fail to colocalize with 88 disease outcomes (Connally et al. 2022). Single-cell sequencing studies (scRNA-seq) assay gene expression in 89 specific cell types and thus single-cell sequencing can provide a less heterogeneous assessment of gene expression. 90 Comparing colocalization between bulk and single-cell sequencing, studying additional variables that influence the 91 association, could resolve the contributory factors. This knowledge could help identify causal genes at GWAS loci 92 and accelerate drug development by targeting pathways causal for disease. Targets supported by MR and 93 colocalization evidence are more likely to anticipate clinical trial results, where the target of the medicine in the trial

Colocalization of expression transcripts with COVID-19 outcomes is dependent on cell-type and cell-state.

94 is a circulating protein and its causal influence upon disease is supported by both MR and colocalization. (Zheng et95 al. 2020).

96 Several studies have investigated the relationship between gene expression and COVID-19 outcomes using 97 older releases of expression data or COVID-19 outcomes. Pairo-Castineira et al. found that increased TYK2 and 98 decreased IFNAR2 expression in whole blood were associated with life-threatening COVID-19 (Pairo-Castineira et 99 al. 2021). Schmiedel et al. found several genes whose expression in specific immune cell types and tissues, 100 including resting and activated naive CD4+ cells, influenced and colocalized with genetic determinants of COVID-101 19 outcomes (Schmiedel et al. 2021). D'Antonio et al. found genes that colocalized with COVID-19 loci in whole 102 blood, including ABO and IFNAR2, and identified the causal variants using fine-mapping (D'Antonio et al. 2021). 103 Recently, Soskic et al. profiled the changes in gene expression in CD4+ T-cells following stimulation with 104 anti-CD3/anti-CD28 human T-activators (Soskic et al. 2022). We aimed to determine if cell and cell-state specific 105 gene expression could identify novel determinants of COVID-19 outcomes, suggesting which cells are responsible 106 for COVID-19 mortality risk and when. Further, we aimed to determine if such cellular specificity may clarify 107 colocalization of expression and GWAS data. Repeating this analysis in other cell types, bulk whole-blood in 108 individuals with symptoms of COVID-19, with and without a recent PCR-confirmed infection, and bulk tissues in 109 individuals assessed prior to the pandemic lacking any symptoms would identify differences in colocalization due to 110 sequencing modality and different clinical states. The results would afford insights into whether the genetic control 111 of gene expression and disease risk is clarified when resolving to single cells, specific cellular states and clinical 112 characteristics of patients sampled.

113 To answer these questions, we undertook a four-stage study design (Fig. 1). First, we conducted Mendelian 114 randomization (MR) of *cis*-eQTLs obtained from single-cell RNA-sequencing (scRNA-seq) data from CD4+ T-cell 115 subtypes at varying times after stimulation with gene expression as exposures and COVID-19 severity as an 116 outcome. Second, we tested these MR-identified genes for colocalization with COVID-19 outcomes across all time 117 points following stimulation of CD4+ T-cells. Third, we compared these colocalization results to those from bulk 118 whole-blood RNA sequencing obtained from individuals with COVID-19 symptoms, who were either SARS-CoV-2 119 PCR positive or negative. Fourth, we compared the colocalization results to bulk unstimulated whole blood and 47 120 other tissues obtained from individuals assessed in GTEx v.8, whose tissues were apparently undiseased at time of 121 sampling.

- 122 These findings identified 33 genes whose expression may influence COVID-19 outcomes. Colocalization
- 123 was highly variable and not consistent across the factors that may influence it. These results underline the
- 124 complexity of factors that influence the colocalization of genetic expression with disease.
- 125
- 126 **Results**:
- 127 Cohort demographics. All datasets used in this study included individuals solely of European ancestry to reduce
- 128 potential confounding by population stratification. ScRNA-seq data for CD4+ T cells in whole blood was obtained
- from Soskic *et al.*, who isolated cells from 119 healthy, British-ancestry individuals, with a mean age of 47 years,
- 130 where 44% were females (Soskic et al. 2022). Bulk whole-blood RNA sequencing of individuals with symptoms of
- 131 COVID-19, who were SARS-CoV-2 positive or negative, was obtained from BQC19, a Quebec cohort of
- 132 individuals recruited from hospitals presenting with COVID-19 symptoms. BQC19 RNA-sequencing data
- 133 comprised 112 individuals with symptoms of COVID-19 and SARS-CoV-2 positive PCR tests and 166 individuals
- 134 who also had symptoms of COVID-19 but a SARS-CoV-2 negative PCR test. The mean age of BQC19 participants
- 135 was 54 years and 53% were females. The GTEx Consortium cohort comprised 838 post-mortem donors, including
- 136 715 individuals of European ancestry, of which 33.5% were female (GTEx Consortium 2020).
- 137
- 138 *MR and sensitivity testing*. To identify genes influencing COVID-19 outcomes, we used either a Wald ratio or
- 139 inverse-variance weighted MR analysis at 81 non-MHC COVID-19 associated loci (Supplemental Table 1) across
- 140 three COVID-19 outcomes (severe disease, hospitalized disease, and susceptibility to disease) with sensitivity
- 141 analyses for each test, detailed in **Methods**. We identified 33 genes whose expression was shown by MR to
- 142 influence COVID-19 severity and susceptibility (Fig. 2, Table 1, Supplemental Table 2).
- 143 *Single-cell results.* Of the 29,430 combinations of CD4+ cell:stimulation-state:gene:outcome for the whole-blood
- single-cell eQTLs, 1,225 transcripts (4.2%) had a multiple-testing, Benjamini-Hochberg adjusted p-value ≤ 0.05 in
- the MR analyses. We limited results to only those arising from *cis*-eQTLs to reduce potential bias from horizontal
- 146 pleiotropy. *Cis*-eQTLs were defined as genetic variants associated with transcript level within ±500 kb of the
- 147 transcriptional start site. We also only retained *cis*-eQTLs that were within \pm 500 kb of the lead SNP associated with
- 148 a COVID-19 outcomes (Supplemental Table 3). Only 13 of these 1,225 *cis*-eQTLs passed colocalization sensitivity
- testing, defined as having a probability of the gene's expression and the COVID-19 outcome sharing a single causal

Colocalization of expression transcripts with COVID-19 outcomes is dependent on cell-type and cell-state.

150	variant (PP _{H4}) greater than 0.80 (Fig. 1-2). These data demonstrate that only a small proportion of <i>cis</i> -single-cell
151	eQTLs identified via MR colocalized with COVID-19 outcomes, suggesting that such MR findings do not
152	consistently reflect a common causal genetic signal shared between the transcript and COVID-19 outcomes.
153	
154	Bulk results. Next, we assessed cis-eQTLs from the bulk whole-blood RNA sequencing in the BQC19 cohort, which
155	comprised individuals with symptoms of COVID-19 who had either a positive, or negative PCR test for SARS-
156	CoV-2. Of the 5,105 combinations of study-group:gene:outcome for the BQC19 cis-eQTLs, 80 transcripts (1.6%)
157	were identified by MR to have effects on COVID-19 outcomes (Supplemental Table 4). Only 4 of these 80
158	transcripts passed colocalization sensitivity testing (Fig. 1-2). We next assessed whether we would observe similar
159	results if we used whole blood and other organ bulk RNA sequencing from GTEx v.8 (GTEx Consortium 2020) as
160	the source of the cis-eQTLs, that included individuals without symptoms or seropositivity for COVID-19. In GTEx
161	bulk whole-blood, we found that of the 2,660 combinations of gene:outcome for the GTEx cis-eQTLs, 75 (2.8%)
162	were identified by MR testing to have effects upon COVID-19 outcomes, with only two colocalizing (Fig. 1-2). In
163	all 48 GTEx tissues, we found that of the 125,088 combinations of tissue:gene:outcome tested, 3190 (2.6%) were
164	estimated to influence COVID-19 outcomes by MR but only 98 of these colocalized (Fig. 2).
165	
166	Thus, taken together, across the three different sources of gene expression data (scRNA-seq whole blood CD4+ T-

167 cells, bulk whole blood RNA sequencing in patients with symptoms of COVID-19, and bulk RNA sequencing in 168 individuals whose tissues were apparently health across 48 tissues, including whole blood), we observed 33 unique 169 putatively causal transcripts across 115 specific states that colocalized, which represent 2.3% of those transcripts 170 that survived MR testing and multiple testing thresholds. These findings suggest that most transcripts identified to be 171 associated with COVID-19 outcomes via MR fail to colocalize even across single cell and bulk sequencing, as well 172 as different cellular states and patient states.

173

MR implicated several cis-eQTLs that increase or decrease the risk for COVID-19 outcomes with few overlapping
transcripts between scRNA-seq and bulk RNA sequencing results. Across outcomes, all cell types from the scRNAseq whole-blood data had at least one *cis*-eQTL estimated to be causal for a COVID-19 outcome via MR, except T
effector memory re-expressing CD45RA and T regulatory cells (Fig. 2). Of the four genes estimated to have

Colocalization of expression transcripts with COVID-19 outcomes is dependent on cell-type and cell-state.

178 colocalized causal effects from the whole-blood scRNA-seq MR experiments, RALGDS expression was the only cis-179 eOTL that decreased the risk of COVID-19 outcomes. Specifically, RALGDS expression reduced the risk of severe 180 disease (OR = 0.78, 95% CI: 0.71-0.87; adjusted p = 1.1×10^{-4}) and susceptibility to disease (OR = 0.88, 95% CI: 181 0.86-0.90; adjusted $p = 7.4 \times 10^{-18}$), when expressed in solely T effector memory cells 16 hours after stimulation 182 (Fig. 2). RALGDS' influence on hospitalized COVID-19 was not clearly different from the null (OR = 0.87, 95% CI: 183 0.79-0.96; adjusted p = 0.08) but passed MR sensitivity testing and colocalized. NAPSA expression in T naive cells 184 40 hours after stimulation increased risk of hospitalized (OR = 1.17, 95% CI: 1.08-1.28; adjusted $p = 5.0 \times 10^{-3}$) and 185 susceptibility to (OR = 1.08, 95% CI: 1.05-1.11; adjusted $p = 1.7 \times 10^{-5}$) COVID-19 (Fig. 2). NAPSA's influence on 186 severe COVID-19 was not different from the null (OR = 1.20, 95% CI: 1.06-1.37; adjusted p = 0.07) but passed MR 187 sensitivity testing and colocalized. NAPSA also increased risk for every outcome in T effector memory cells 40 188 hours after stimulation (OR = 1.18, 95% CI: 1.10-1.27; adjusted $p = 4.0 \times 10^4$ for severe, OR = 1.15, 95% CI: 1.10-1.27;

189 1.20; adjusted $p = 5.9 \times 10^{-9}$ for hospitalized, OR = 1.04, 95% CI: 1.03-1.06; adjusted $p = 1.2 \times 10^{-4}$ for

190 susceptibility) (**Fig. 2**).

191 Interestingly, none of the colocalizing transcripts from scRNA-seq overlapped with colocalizing bulk RNA 192 sequencing cis-eQTLs from BQC19 or GTEx in matching tissues. Generally, signals in bulk sequencing were harder 193 to separate from noise, compared to single-cell results. Increased IFNAR2 expression was protective in individuals 194 with symptoms of COVID-19 without PCR-confirmed SARS-CoV-2 against severe COVID-19, or individuals who 195 were negative for or had perhaps not yet tested positive for COVID-19 (OR = 0.75, 95% CI: 0.66-0.86; adjusted p = 196 3.0×10^{-3}) with insufficient evidence to suggest protection for individuals who did test positive (adjusted p = 0.04) 197 where it failed weighted mode MR sensitivity testing but colocalized. In contrast, *IFNAR2* was protective for only 198 individuals who tested positive for SARS-CoV-2 against hospitalized COVID-19 (OR = 0.86, 95% CI: 0.80-0.94; 199 adjusted p = 0.03) with insufficient evidence to suggest protection for BQC19 SARS-CoV-2 negative individuals 200 (adjusted $p = 8.1 \times 10^{-3}$) where it failed MR Egger intercept sensitivity testing (p = 0.02) while colocalizing (Fig. 2). 201 This was perhaps a false negative. There were several other genes that colocalized for only a subset of outcomes in 202 other tissues, although some consistently colocalized in the same tissue across outcomes, such as ABO in the testis 203 and DPP9 in sun-exposed skin (Table 1, Supplemental Table 2).

Colocalization of expression transcripts with COVID-19 outcomes is dependent on cell-type and cell-state.

205 Colocalization of specific MR-identified cis-eQTLs depended on cell stimulation. To investigate the variables that 206 influenced colocalization, we conducted colocalization on each gene that was estimated causal in MR. Most MR-207 identified transcripts did not colocalize (Fig. 1, Supplemental Tables 6-8). The proportion of estimated causal 208 transcripts that colocalized and passed single causal variant sensitivity testing was 1.1% for whole blood single-cell 209 eQTLs, 5.0% for BQC19, 2.7% for GTEx whole blood, and 3.1% for all organs in GTEx (Fig. 3). Colocalization of 210 2/4 single-cell eQTLs was specific to cell type (Fig. 2) with 3/3 from stimulated cells specific to cell state with 211 colocalization for RALGDS, for example, specific to T effector memory cells 16 hours post-stimulation for severe 212 and susceptibility to COVID-19 (Fig. 4). 213 Colocalization of transcripts occurred at varying times following stimulation (Fig. 2). Colocalization did 214 not appear to depend on SARS-CoV-2 PCR result in BQC19 among individuals with symptoms of COVID-19, as 215 seen with IFNAR2 (Fig. 2, Fig. 5). Colocalization of select transcripts appeared organ specific, as with MUC5B 216 (Fig. 6), although there was more noise in bulk sequencing data, as was observed for ABO. Specifically, ABO 217 colocalized in some organs for only a single outcome and *IL10RB* tested in GTEx had an opposite direction of effect 218 in cultured fibroblasts than tibial nerve (Fig. 2). 219 While many transcripts did not colocalize, many transcripts that did have evidence of the single causal 220 variant assumption being violated, with multiple peaks present within or close to the cognate 1 Mb window, 221 suggesting bias due to linkage disequilibrium (Fig. 7). Of 19 colocalizing transcripts in single-cell CD4+ T cells, 6 222 had evidence of violating this assumption. Of 9 colocalizing transcripts in bulk whole blood from patients with 223 symptoms of COVID-19 in BQC19, we observed 6 that violated this assumption. Of 4 from bulk whole blood in 224 GTEx, 2 violators. Of 378 from all tissues in GTEx, 265 transcripts violated this assumption. These results underpin 225 the limitations of present study sample sizes and existing methods designed to clarify causal colocalizing expression 226 signals. 227 228 Discussion: 229 In this study, we attempted to identify factors that influence colocalization of cis-eQTL MR findings for 230 COVID-19 outcomes. Most MR-identified single-cell eQTLs and bulk eQTLs did not colocalize, suggesting that 231 linkage disequilibrium and limited study sizes yielding fewer converging signals may strongly impact the validity of 232 eQTL MR studies that assess colocalization, and necessitate more stringent quality control. Previous research has

Colocalization of expression transcripts with COVID-19 outcomes is dependent on cell-type and cell-state.

demonstrated a lack of colocalization of expression findings and suggested that this may be resolved by single-cell
eQTL analyses, assessing stimulation state, or clearly defining the state of the individual when blood samples were
drawn. Here we show that colocalization of these signals is highly variable, and it is not fully explained by changing
cell type, cell stimulation, symptoms of COVID-19, or organ. Taken together, these findings suggest that
colocalization of eQTLs with disease outcomes is difficult using current technologies, reference panels and
statistical methods, and with present study sample sizes that in single-cell studies typically is limited to 100
individuals.

240 While we overall found colocalization to be limited, our results were reassuring in that we observed some 241 trends and results consistent with past studies and hypotheses (Fig. 2) (Connally et al. 2022; Soskic et al. 2022). For 242 putatively causal transcripts from CD4+ T cells in whole blood, colocalization was influenced by cell stimulation, or 243 cell state (Fig. 2a), like other groups' observations when conducting colocalization without MR (Soskic et al. 2022). 244 On comparing putatively causal transcripts between single-cell and bulk results, with the latter evaluating transcripts 245 in several different cells in a matching tissue, we found no overlap between the modalities in the same tissue, that 246 could suggest that sequencing modality plays a role (Fig. 2). Genes that colocalized in CD4+ T cells did not 247 colocalize in spleen that is enriched with T cells (Fig. 2). This could underscore the impact of sequencing multiple 248 cell types in bulk sequencing, suggesting that results must be contextualized against sequencing modality and 249 sample cellular heterogeneity. We found organ to play a moderate role in colocalization when comparing putatively 250 causal genes in GTEx (Fig. 2b), supporting others' findings with non-COVID-19 outcomes (Rocheleau et al. 2022). 251 The data on organs' roles were perhaps noisy. While we found outcome to have a limited role in influencing 252 colocalization for select transcripts, different from others (Rocheleau et al. 2022; Soskic et al. 2022), this could be 253 due to the greater similarity in our outcomes.

This paper has limitations. The scRNA-seq data came from cells stimulated by a standard T cell stimulator
rather than SARS-CoV-2. Such stimulation has been employed by several existing works studying immunity in
COVID-19 (De Biasi et al. 2020; Kundu et al. 2022; Mathew et al. 2020) and may have some relevance to the
stimulation endured when T-cells encounter SARS-CoV-2. We only investigated CD4+ T cells in whole blood (Fig.
2). There are other cell types present in greater proportions, which could explain the minimal overlap in
colocalization between our single-cell and bulk sequencing results. We could only locate whole blood *cis*-sceQTLs
from an admixed study that did not release ancestry-stratified results (Randolph et al. 2021). Ancestry-stratified

Colocalization of expression transcripts with COVID-19 outcomes is dependent on cell-type and cell-state.

261	results are important for Mendelian randomization and colocalization to limit bias from indirect pleiotropic
262	mechanisms, including linkage disequilibrium that varies by ancestral group. Our GTEx results show that many
263	tissues could contribute to COVID-19 outcomes and pathogenesis (Fig. 2). Single-cell analysis of all tissues,
264	particularly lung, could help understand the multi-system basis of post-COVID-19 syndrome (Mehandru and Merad
265	2022). We were unable to access single-cell lung data for this work (Lamontagne et al. 2018). Our outcomes were
266	limited to COVID-19 severity and susceptibility, when expression could also influence complications of COVID-19,
267	such as post-COVID-19 syndrome and schizophrenia (Baranova et al. 2022b; Mehandru and Merad 2022). We have
268	developed two-step MR methods that link gene expression to COVID-19 outcomes, and then to these complications
269	(Yoshiji et al. 2023), which has already been used to validate BMI's role on COVID-19 outcomes as discovered by
270	others (Baranova et al. 2023).

271 Our study was limited to individuals of European ancestry. While the HGI has found loci with genome-272 significant variants in other ancestries, none of the loci from Admixed American, African, East Asian, or South 273 Asian ancestry for any outcome overlapped with loci found to influence COVID-19 outcomes in this study. Given 274 fewer loci in non-European datasets, this could be due to sample size and underscores the importance of multi-275 ancestry analyses. However, even within European ancestry individuals, subtle differences in LD patterns can 276 influence colocalization, which we observed (Fig. 4-6) (Kanai et al. 2022; Kanai et al. 2021). Such differences may 277 have impacted the lack of colocalization observed here. Sample size was limited for the eQTL datasets that we 278 employed, which increases the risk of biased results, which we possibly observed where some genes colocalized for 279 only a single outcome or did not colocalize in one outcome (Fig. 2). We adjusted for this by using methods well 280 established in the literature, including several stringent and conservative sensitivity tests and means of quality 281 control for MR and colocalization. While using a colocalization window around a lead variant of ±500 kb is more 282 likely to limit bias from pleiotropy, it increases the risk of missed signals. Data must still be carefully appraised for 283 possible false positives, as may be the case with *IL10RB* being estimated protective in cultured fibroblasts for all 284 outcomes but increasing the risk of COVID-19 outcomes in the tibial nerve for all outcomes (Fig. 2).

While we found symptoms of COVID-19 to influence genomic colocalization for select transcripts and states, as shown by *IFNAR2* between severe and hospitalized COVID-19, this trend could have been influenced by a batch effect. SARS-CoV-2 status' effect on colocalization among individuals in BQC19 could be biased as negative results could represent false negatives and individuals with COVID-19 symptoms could have had a different viral

Colocalization of expression transcripts with COVID-19 outcomes is dependent on cell-type and cell-state.

- illness. We mitigated this by deriving eQTLs using the same pipeline used by GTEx and limiting the conclusions we
- 290 made given this context (GTEx Consortium 2020). Generally, we investigated variables in multiple datasets, given
- that a variable's demonstrated role in multiple cohorts supports making a generalization.
- 292
- 293 Conclusions: While existing hypotheses suggest that colocalization of transcripts depends on multiple conditions,
- 294 we found that *cis*-eQTLs identified by MR for COVID-19 outcomes rarely colocalized, even when assessing
- different cell types, cell states, symptoms of COVID-19 and organs. Taken together, these findings suggest that
- even after accounting for variables, there was little evidence of colocalization for most genes whose influence on
- 297 COVID-19 outcomes was identified through MR.
- 298

299 Figure Captions

300 Fig. 1. Study overview

301 Fig. 2. A total of 33 genes that colocalized across body tissue, evaluated at the (a) single-cell and (b) bulk tissue

302 level, were estimated to have their expression increase (red) and decrease (blue) risk of COVID-19 outcomes. In

303 bulk tissue, COVID+ referred to individuals who had tested positive for COVID-19 with COVID- for those who

304 tested negative and Symptoms+ refers to individuals who presented with symptoms of COVID-19 with Symptoms-

305 referring to those who did not have symptoms of COVID-19. Note that some transcripts show increased expression

306 in some tissues to be associated with COVID-19 outcomes, whereas other tissues show decreased expression to be

307 associated with the same transcript for the same outcome. TCM: T central memory cell. TEM: T effector memory

308 cell. TN: T naïve cell.

309 Fig 3. The proportion of estimated causal variants that colocalized and passed sensitivity testing. Orange bars refer

310 to single cell data, gray bulk sequencing.

311 Fig 4. Locuszoom plots for *RALGDS* in the setting of variable cell stimulation and cell type, with selected variant of

312 rs8176719. *RALGDS* was estimated causal with colocalization for only T effectory memory (TEM) cells 16 hours

313 post-stimulation, highlighting the role of cell stimulation on colocalization. A * indicates a dataset that colocalized.

- 314 rs8176719 was not detected in T naïve cells 16 hours post-stimulation, so rs7036642 was highlighted, which is in
- **315** LD with rs8176719.

316	Fig 5. Locuszoom plots for IFNAR2 in the setting of variable presence of COVID-19 symptoms and SARS-CoV-2
317	positivity, with selected variant of rs9636867. IFNAR2 was estimated causal and colocalized only in patients with
318	COVID-19 symptoms (Symptoms +/-) with SARS-CoV-2 status (COVID +/-) having a less apparent role. A *
319	indicates a dataset that colocalized.
320	Fig 6. Locuszoom plots for MUC5B in the setting of variable organ in GTEx v8, with selected variant of
321	rs35705950. MUC5B was estimated causal and colocalized only in lung for severe COVID-19. There were no cis-
322	eQTLs for whole blood.
323	Fig 7. Percentage of colocalizing results ($PP_{H4} \ge 0.80$) that had evidence of violating the single causal variant
324	assumption. Orange bars refer to single cell data, gray bulk sequencing.
325	
326	
327	
328	Table Captions
329	Table 1. Putatively causal associations of gene expression with COVID-19 outcomes. While some genes had
330	opposite effects on risk for a minority of tissues (bolded), the direction of effect of most was consistent when
331	observed in multiple tissues.
332	
333	Supplemental Table Captions
334	Supplemental Table 1. All lead variants in HGI European-ancestry data, excluding MHC loci.
335	Supplemental Table 2. All genes that were estimated causal and colocalized in our study, with existing evidence
336	linking genes to outcomes.
337	Supplemental Table 3. All MR results using CD4+ T cell expression data.
338	Supplemental Table 4. All MR results using expression data from individuals with symptoms of COVID-19 in
339	BQC19.
340	Supplemental Table 5. All MR results using expression data from all tissues in GTEx.
341	Supplemental Table 6. All colocalization results of putatively causal variants from CD4+ T cell expression data.
342	Supplemental Table 7. All colocalization results of putatively causal variants from individuals with symptoms of
343	COVID-19 in BQC19.

Colocalization of expression transcripts with COVID-19 outcomes is dependent on cell-type and cell-state.

- **344** Supplemental Table 8. All colocalization results of putatively causal variants from all tissues in GTEx.
- 345
- 346 Methods:
- 347 Datasets. We examined *cis*-eQTLs in three datasets to implicate their influence on COVID-19 outcomes and
- 348 investigate how experimental and physiological conditions impact colocalization (Fig. 1). scRNA-seq *cis*-eQTLs
- 349 from Soskic *et al.* were used to analyze how cell type, cell stimulation, and cell microenvironment affected
- 350 colocalization (Soskic et al. 2022). Bulk RNA-seq *cis*-eQTLs from Biobanque Quebecoise de la COVID-19
- 351 (BQC19) were used to investigate how disease state impacted identified *cis*-eQTLs and colocalization in individuals
- 352 with symptoms of COVID-19, with and without PCR-confirmed SARS-CoV-2 infection. Bulk RNA-seq *cis*-eQTLs
- 353 from GTEx whole blood were used to compare BQC19 data with data from individuals without symptoms of
- 354 COVID-19 with all other organs used to determine the role of organ (GTEx Consortium 2020).
- 355

356 Whole-blood single-cell eOTLs. The summary statistics for immune cell expression cis-eOTLs before and after 357 stimulation with anti-CD3/anti-CD28 human T-Activators were obtained from Soskic et al. (Soskic et al. 2022). The 358 study consisted of 119 individuals of British ancestry with peripheral blood mononuclear cells (655,349 CD4+ T 359 cells) sequenced using scRNA-seq (Soskic et al. 2022). We used the summary statistics for cells at all available time 360 points (unstimulated, 16 hours post-stimulation corresponding to before cell division, 40 hours post-stimulation 361 corresponding to after cell division, five days post-stimulation corresponding to gaining effector function) for cell 362 types present before stimulation and present for at least one time point after stimulation (Soskic et al. 2022). The 363 unstimulated time point acted as a control for stimulation, sequenced 16 hours after culturing without any anti-364 CD3/anti-CD28 human T-Activators (Soskic et al. 2022). We investigated CD4+ antigen-I and CD4+ memory cell 365 classifications before Leiden-algorithm clustering, implemented by Soskic et al., and T I, T central memory, T 366 effector memory, CD45RA re-expressing T effector memory, and thymus-derived regulatory T cells after clustering 367 (Soskic et al. 2022). Full details describing RNA sequencing, separation of cell types and stimulation are available 368 in Soskic et al. (Soskic et al. 2022).

Bulk whole blood eQTLs from subjects with symptoms of COVID-19, with and without SARS-CoV-2 positive PCR
 results. BQC19 (https://en.quebeccovidbiobank.ca) is a prospective cohort enrolling participants with PCR-proven
 SARS-CoV-2 infection and PCR-proven SARS-CoV-2 negative individuals who presented to the hospital with signs

Colocalization of expression transcripts with COVID-19 outcomes is dependent on cell-type and cell-state.

372	or symptoms consistent with COVID-19. Participants were recruited from eight academic hospitals in the province
373	of Quebec, Canada. A total of 4,704 participants underwent PCR testing with confirmed positive or negative results
374	between January 25th, 2020 to March 20th, 2022. A total of 379 participants had RNA extracted and sequenced with
375	eQTLs called using the GTEx pipeline, available from the Broad Institute (https://github.com/broadinstitute/gtex-
376	pipeline/tree/master/qtl). We used data solely for those of non-Finnish European ancestry, which included 112
377	SARS-CoV-2 positive and 166 SARS-CoV-2 negative samples.
378	
379	GTEx release 8 data. We obtained cis-eQTL summary statistics for GTEx release 8 for whole-blood and all other
380	organs, restricted to individuals of European ancestry, from: https://www.gtexportal.org/home/ (GTEx Consortium
381	2020).
382	
383	COVID-19 Outcome Data. European-ancestry-specific summary statistics for COVID-19 outcomes were obtained
384	from the COVID-19 Host Genetics Initiative (HGI) release 7 (https://www.covid19hg.org/), which did not include
385	individuals from 23AndMe (Covid-19 Host Genetics Initiative 2021). The COVID-19 outcomes included severe
386	COVID-19 (13,769 cases and 1,072,442 controls), COVID-19 hospitalization (32,519 cases and 2,062,805 controls).
387	and susceptibility to COVID-19 (122,616 cases and 2,475,240 controls). Severe COVID-19 was defined as COVID-
388	19 requiring respiratory support or resulting in death. COVID-19 with hospitalization was defined as an infection
389	requiring hospitalization or death. COVID-19 susceptibility was defined as infection determined by self-report on a
390	questionnaire, electronic medical record diagnosis, or laboratory testing (serology tests or nucleic acid
391	amplification). Controls were all individuals who did not meet an outcome's definition.
392	
393	MR of <i>cis</i> -eQTLs with COVID-19 outcomes. We used MR to estimate the causal relationship between exposures


(which here are RNA transcript levels) and COVID-19 outcomes to determine how cell type, cell stimulation, time
after stimulation, symptoms of COVID-19, PCR result for SARS-CoV-2 among individuals with symptoms of
COVID-19, and organ influenced the relationship between gene expression and COVID-19 outcomes. MR studies
use SNPs strongly associated with an exposure as instrumental variables to estimate the effect of an exposure on an
outcome. Such studies reduce potential confounding effects because genetic variants are essentially randomized at
conception. They also prevent bias due to reverse causation (wherein the outcome influences the exposure) since the

400	assignment of genetic variants always precedes disease onset (Smith and Ebrahim 2003). The main assumptions of
401	MR are that the variants under study are strongly associated with the risk factor of interest, confounders of the
402	exposure-outcome relationship are not associated with the variants, and the variants only affect the outcome through
403	the risk factor (Davies et al. 2018; Skrivankova et al. 2021). The most problematic of these assumptions is the last,
404	as it is difficult to confidently understand if the SNPs affect the outcome independent of the exposure (i.e. a lack of
405	horizontal pleiotropy). To partially mitigate against such potential bias, we have used only cis-eQTLs, which are
406	more likely to act directly through the transcription or translation of the proximal gene, rather than through
407	horizontally pleiotropic pathways. There was overlap of individuals from the cis-eQTL studies with individuals in
408	the HGI data.
409	To undertake MR analyses, we used the TwoSampleMR (v0.5.6) package
410	(<u>https://mrcieu.github.io/TwoSampleMR/</u>). First, we identified all genome significant ($p \le 5 \ge 10^{-8}$) loci from HGI
411	COVID-19 summary statistics. We isolated all variants 500 kb upstream and downstream of the lead HGI variant for
412	each locus for each exposure and outcome. Second, we excluded the MHC locus (chr $6: 28,510,120 - 33,480,577;$
413	GRCh38) to reduce potential confounding by linkage disequilibrium structure. Third, the exposure <i>cis</i> -eQTLs, ±500
414	kb from their transcriptional start sites, for each cell type, cell stimulation state, cell stimulation time, SARS-CoV-2
415	status, presence of COVID-19 symptoms, and gene were filtered for variants in LD using the package's clumping
416	function with default settings. Fourth, the exposure data were harmonized with outcome data using default settings.
417	Fifth, we conducted MR with sensitivity tests. For loci with only one remaining cis-eQTL following harmonization,
418	we applied Wald Ratio-based MR. For loci with more than one remaining independent cis variant, we used inverse-
419	variance weighted MR (MR-IVW). For loci with three or more remaining cis-eQTLs, we did sensitivity testing
420	using exposure MR weighted median, MR weighted penalized median, MR weighted mode, MR Egger regression,
421	and MR Egger intercept. MR Steiger was done for every test to assess for reverse causation, wherein the MR results
422	would be better explained by the effects of COVID-19 on the cis-eQTL. Results were retained for downstream
423	analysis if they passed these sensitivity tests with a Wald Ratio or IVW Benjamini-Hochberg adjusted p-value,
424	which controls the false-discovery rate by adjusting the p-value by the number of tests, less than or equal to 0.05.
425	
426	Colocalization. To investigate whether cis-eQTLs shared the same single causal signal with COVID-19 outcomes,
427	we used coloc v5.1.1 (https://chr1swallace.github.io/coloc/). Colocalization helps to guard against bias due to


428	confounding from linkage disequilibrium. Such confounding can occur when the SNPs that influence an exposure
429	(here cis-eQTLs) do not causally influence an outcome (here COVID-19 outcomes) but are associated with each
430	other due to linkage disequilibrium. Consistent with Soskic et al., we required at least 50 variants for each
431	colocalization analysis (Soskic et al. 2022). We employed default priors of $p_1=p_2=10^{-4}$ and $p_{12}=10^{-5}$ where p_1 is the
432	prior probability that only eQTLs had a genetic association in the region, p_2 is a prior probability that only the HGI
433	summary statistics had a genetic association in the region, and p_{12} is the prior probability that the eQTL data and the
434	HGI summary statistics shared the same genetic associations in the region. A $p_{12} \ge 0.8$, or $PP_{H4} \ge 0.8$ was
435	considered evidence of colocalization. Sensitivity tests were conducted using coloc's sensitivity test function for
436	each instance of colocalization to validate the single causal variant assumption and evaluate the robustness of results
437	to different prior settings. Locuszoom plots used to highlight trends were produced using Locuszoom (Pruim et al.
438	2010).
439	
440	Ethics statement. Soskic et al. biological samples were ethically sourced and used in research under an institutional
441	review board-approved protocol (Soskic et al. 2022). BQC19 received ethical approval from the Jewish General
442	Hospital research ethics board (2020-2137) and the Centre Hospitalier de l'Université de Montréal institutional
443	ethics board (MP-02-2020-8929, 19.389). Specimens collected by GTEx were sourced per protocol for an
444	institutional review board (GTEx Consortium 2020).
445	
446	Data availability. Data from Soskic et al. are available through Zenodo (doi:10.5281/zenodo.6006796). BQC-19
447	data, including expression data, is available by application: https://www.bqc19.ca/. GTEx release 8 data is available
448	from: https://www.gtexportal.org/home/. COVID-19 HGI summary statistics are available from:
449	https://www.covid19hg.org/.
450	
451	Code availability. All analyses were conducted in R v4.0.5 (R Core Team 2021). Code is available at:
452	https://github.com/richardslab/dynamic QTL COVID19.
453	
454	Acknowledgements. JDSW is a graduate student in McGill's Quantitative Life Sciences Ph.D. program. This work
455	was made possible through open sharing of data and samples from BQC19. We thank all participants of BQC19 for

Colocalization of expression transcripts with COVID-19 outcomes is dependent on cell-type and cell-state.


456	their contribution. We thank Vincent Mooser, director of BQC19, for his contributions organizing BQC19. Some
457	transcriptomics sequencing was performed at the McGill University Genome Centre (Montreal, Quebec, Canada) by
458	Ariane Boisclair, Janick St-Cyr, Pouria Jandaghi, Daniel Auld. The remainder of the transcriptomics sequencing was
459	performed at the Centre d'expertise et de services Génome Québec (Montreal, Quebec, Canada), facilitated by the
460	diligent work of Alexandre Montpetit, Isabelle Guillet, Joelle Fontaine, Martine Lavoie, and Genevieve DonPierre.
461	Kevin Liang contributed to paper revisions.
462	
463	Funding sources. This work is supported by the CIHR (JDSW CIHR 476575). BQC19 was funded by the Fonds de
464	recherche du Québec - Santé, Génome Québec and the Public Health Agency of Canada. The Richards research
465	group is supported by the Canadian Institutes of Health Research (CIHR: 365825; 409511, 100558, 169303), the
466	McGill Interdisciplinary Initiative in Infection and Immunity (MI4), the Lady Davis Institute of the Jewish General
467	Hospital, the Jewish General Hospital Foundation, the Canadian Foundation for Innovation, the NIH Foundation,
468	Cancer Research UK, Genome Québec, the Public Health Agency of Canada, McGill University, Cancer Research
469	UK [grant number C18281/A29019] and the Fonds de Recherche Québec Santé (FRQS). JBR is supported by a
470	FRQS Mérite Clinical Research Scholarship. Support from Calcul Québec and Compute Canada is acknowledged.
471	These funding agencies had no role in the design, implementation or interpretation of this study.
472	Disclosures: JBR's institution has received investigator-initiated grant funding from Eli Lilly, GlaxoSmithKline and
473	Biogen for projects unrelated to this research. He is the CEO of 5 Prime Sciences (<u>www.5primesciences.com</u>),
474	which provides research services for biotech, pharma and venture capital companies for projects unrelated to this
475	research.
476	








Colocalization of expression transcripts with COVID-19 outcomes is dependent on cell-type and cell-state.




Colocalization of expression transcripts with COVID-19 outcomes is dependent on cell-type and cell-state.

487 Table 1.


Gene	Putatively causal cell/tissue	Existing evidence
ABO	Adrenal gland (Severe) – Hazardous	MR in non-GTEx and GTEx eQTL and
	Artery tibial (Severe) – Hazardous	pQTL datasets for lung and whole
	Breast Mammary Tissue (Susceptible) – Hazardous	blood (Baranova et al. 2022a;
	Esophagus mucosa (Susceptible) – Hazardous	Hernandez Cordero et al. 2021)
	Esophagus muscularis (Severe) – Hazardous	
	Heart Left Ventricle (Severe and Hospitalized) - Hazardous	
	Liver (Hospitalized) – Hazardous	
	Muscle skeletal (Severe) – Hazardous	
	Testis (All) – Hazardous	
	Whole blood COVID+ Symptoms+ (Hospitalized) – Protective	
ATP5PO	Lung (Hospitalized) – Hazardous	Associational (Li et al. 2022)
GBAP1	Breast Mammary Tissue (Susceptible) – Hazardous	MR with colocalization for splice
	Cultured Fibroblasts (Susceptible) – Hazardous	isoform (Nakanishi et al. 2022)
	Colon Sigmoid (Susceptible) – Hazardous	
	Lung (Susceptible) – Hazardous	
	Nerve Tibial (Susceptible) – Hazardous	
	Small Intestine Terminal Ileum (Susceptible) – Hazardous	
	Stomach (Susceptible) – Hazardous	
HIP1	Breast mammary tissue (Severe) – Hazardous	None
	Nerve tibial (Severe) – Hazardous	1.010
	Whole blood COVID- Symptoms- (Severe) – <u>Protective</u>	
IFNAR2	Cells cultured fibroblasts (Severe and hospitalized) – Protective	MR with colocalization for GTEx v.7
11 10/11(2	Esophagus mucosa (Susceptible) – Protective	eQTLs and pQTLs for whole-blood an
	Whole blood COVID- Symptoms+ (Hospitalized) – Protective	lung (Baranova et al. 2021; Fricke-
	Whole blood COVID+ Symptoms+ (Revere) – Protective	Galindo et al. 2022; Krishnamoorthy e
		al. 2023; Liu et al. 2021; Pairo-
		Castineira et al. 2021)
IL10RB	Cells Cultured fibroblasts (All) – <u>Protective</u>	MR with colocalization for eQTLs and
	Esophagus Gastroesophageal junction (All) – Hazardous	pQTLs, did not study excitatory
	Skeletal muscle (Susceptible) – Hazardous	neurons (Gaziano et al. 2021)
	Nerve tibial (All) – Hazardous	ficurons (Suziano et al. 2021)
RAB2A	Adipose subcutaneous (Hospitalized) – Hazardous	MR and colocalization for pQTLs, but
ICID2/1	Artery aorta (Hospitalized) – Hazardous	not for eQTLs (Pietzner et al. 2022)
	Artery tibial (Hospitalized) – Hazardous	
	CD4 Memory Stim 40h (Hospitalized) – Hazardous	
	CD4 Naïve Stim 16h (Hospitalized) – Hazardous	
	CD4 Naïve Stim 40h (Hospitalized) – Hazardous	
	Esophagus mucosa (Hospitalized) – Hazardous	
	Esophagus muccoa (Hospitalized) – Hazardous	
	Liver (Hospitalized) – Hazardous	
	Lung (Hospitalized) – Hazardous	
	Skin not sun exposed (Hospitalized) – Hazardous	
	T naïve Stim 40h (Hospitalized) – Hazardous	
RALGDS	T effect memory Stim 16h (Severe and Susceptible) – Protective	None
WNT3	Adrenal Gland (Hospitalized) – Hazardous	Fine mapped (Wu et al. 2021)
VV IV I J		Time mapped (wu et al. 2021)
	Artery Aorta (Severe and Hospitalized) – <u>Protective</u>	
	Colon Transverse (Severe) – Hazardous	
	Nerve Tibial (Severe) – Hazardous	
88	Thyroid (Severe and Hospitalized) – Hazardous	








493




Colocalization of expression transcripts with COVID-19 outcomes is dependent on cell-type and cell-state.



.

Colocalization of expression transcripts with COVID-19 outcomes is dependent on cell-type and cell-state.



Colocalization of expression transcripts with COVID-19 outcomes is dependent on cell-type and cell-state.

502 Supplemental Table 2.

Gene	Colocalizing cell/tissue	Existing evidence
ABO	Adrenal gland (Severe) - Hazardous	MR in non-GTEx and GTEx eQTL and
	Artery tibial (Severe) – Hazardous	pQTL datasets for lung and whole
	Breast Mammary Tissue (Susceptible) – Hazardous	blood (Baranova et al. 2022a;
	Esophagus mucosa (Susceptible) - Hazardous	Hernandez Cordero et al. 2021)
	Esophagus muscularis (Severe) - Hazardous	
	Heart Left Ventricle (Severe and Hospitalized) – Hazardous	
	Liver (Hospitalized) - Hazardous	
	Muscle skeletal (Severe) - Hazardous	
	Testis (All) - Hazardous	
	Whole blood COVID+ Symptoms+ (Hospitalized) - Protective	
ADAM15	T central memory Stim 5d (Susceptible) - Hazardous	MR with colocalization in GTEx did
		not observe colocalization (Wang et al.
		2022)
ATP11A	Artery Aorta (Hospitalized) - Protective	Fine mapping (Kousathanas et al. 2022)
ATP5PO	Lung (Hospitalized) - Hazardous	Associational (Li et al. 2022)
CNPY4	Testis (Severe) - Protective	None
COPS6	Esophagus muscularis (Hospitalized) - Protective	None
DLX3	Lung (Hospitalized) - Hazardous	MR with colocalization in lung
DLAJ	Lung (mosphanzed) - mazardous	(Hernandez Cordero et al. 2021)
DPP9	Skin sun exposed lower leg (All) - Protective	Associational data in blood (Sharif-Zak
DFF9	Skill sull exposed lower leg (All) - Flotective	et al. 2022)
EAMSEC	Econhomo mucularia (Succentible) Horondous	,
FAM55C	Esophagus muscularis (Susceptible) - Hazardous	None
GBA	Nerve Tibial (Susceptible) - Hazardous	None
CD4 D1	Thyroid (Susceptible) - Hazardous	
GBAP1	Breast Mammary Tissue (Susceptible) - Hazardous	MR with colocalization for splice
	Cultured Fibroblasts (Susceptible) - Hazardous	isoform (Nakanishi et al. 2022)
	Colon Sigmoid (Susceptible) - Hazardous	
	Lung (Susceptible) - Hazardous	
	Nerve Tibial (Susceptible) - Hazardous	
	Small Intestine Terminal Ileum (Susceptible) - Hazardous	
	Stomach (Susceptible) - Hazardous	
HIP1	Breast mammary tissue (Severe) - Hazardous	None
	Nerve tibial (Severe) - Hazardous	
	Whole blood COVID- Symptoms- (Severe) - Protective	
IFNAR2	Cells cultured fibroblasts (Severe and hospitalized) - Protective	MR with colocalization for GTEx v.7
	Esophagus mucosa (Susceptible) - Protective	eQTLs and pQTLs for whole-blood and
	Whole blood COVID- Symptoms+ (Hospitalized) - Protective	lung (Baranova et al. 2021; Fricke-
	Whole blood COVID+ Symptoms+ (Severe) - Protective	Galindo et al. 2022; Krishnamoorthy et
		al. 2023; Liu et al. 2021; Pairo-
		Castineira et al. 2021)
IL10RB	Cells Cultured fibroblasts (All) - Protective	MR with colocalization for eQTLs and
	Esophagus Gastroesophageal junction (All) - Hazardous	pQTLs, did not study excitatory
	Skeletal muscle (Susceptible) - Hazardous	neurons (Gaziano et al. 2021)
	Nerve tibial (All) - Hazardous	
KCNC3	Tibial nerve (Severe and Hospitalized) – Hazardous	TWAS (Krishnamoorthy et al. 2023)
LINC01301	Breast mammary tissue (Hospitalized) – Protective	TWAS (Pairo-Castineira et al. 2022)
	Skin not sun exposed (Hospitalized) - Protective	
LINC02210	Artery tibial (Severe) – Protective	MR with colocalization (Baranova et al.
LINCO2210	Artery usian (Severe) – Protective	2021)
Lnc-INTS12-1	Artery aorta (Severe) – Protective	None
	Thyroid (Severe) - Protective	
Lnc-THBS3-1	Whole blood COVID- Symptoms- (Susceptible) - Protective	None
MAMSTR	Skin Sun Exposed (Hospitalized) – Protective	TWAS (Krishnamoorthy et al. 2023)

Colocalization of expression transcripts with COVID-19 outcomes is dependent on cell-type and cell-state.

shnamoorthy et al. 2023) only for lung eQTLs GTEx release in et al. 2021) with colocalization for eQTLs, did tudy CD4+ T cells (Degenhardt et 022) e e with colocalization of eQTL and L (Zhou et al. 2021) ccalization (D'Antonio et al. 2021) and colocalization for pQTLs, but for eQTLs (Pietzner et al. 2022)
tudy CD4+ T cells (Degenhardt et 022) e e with colocalization of eQTL and L (Zhou et al. 2021) calization (D'Antonio et al. 2021) and colocalization for pQTLs, but
e with colocalization of eQTL and L (Zhou et al. 2021) calization (D'Antonio et al. 2021) and colocalization for pQTLs, but
with colocalization of eQTL and L (Zhou et al. 2021) calization (D'Antonio et al. 2021) and colocalization for pQTLs, but
L (Zhou et al. 2021) calization (D'Antonio et al. 2021) and colocalization for pQTLs, but
and colocalization for pQTLs, but
e
2
WAS linked (Covid-19 Host etics Initiative 2022)
AS (Severe Covid et al. 2020)
mapped (Wu et al. 2021)
1

Baranova A, Cao H, Chen J, Zhang F (2022a) Causal Association and Shared Genetics Between Asthma
and COVID-19. Front Immunol 13: 705379. doi: 10.3389/fimmu.2022.705379
Baranova A, Cao H, Teng S, Zhang F (2023) A phenome-wide investigation of risk factors for severe

509 COVID-19. J Med Virol 95: e28264. doi: 10.1002/jmv.28264

Baranova A, Cao H, Zhang F (2021) Unraveling Risk Genes of COVID-19 by Multi-Omics Integrative
 Analyses. Front Med (Lausanne) 8: 738687. doi: 10.3389/fmed.2021.738687

- Baranova A, Cao H, Zhang F (2022b) Severe COVID-19 increases the risk of schizophrenia. Psychiatry
 Res 317: 114809. doi: 10.1016/j.psychres.2022.114809
- 514 Connally NJ, Nazeen S, Lee D, Shi H, Stamatoyannopoulos J, Chun S, Cotsapas C, Cassa CA, Sunyaev
 515 SR (2022) The missing link between genetic association and regulatory function. Elife 11. doi: 10.7554/eLife.74970
- 517 Covid-19 Host Genetics Initiative (2021) Mapping the human genetic architecture of COVID-19. Nature
 518 600: 472-477. doi: 10.1038/s41586-021-03767-x
- 519 Covid-19 Host Genetics Initiative (2022) A first update on mapping the human genetic architecture of
 520 COVID-19. Nature 608: E1-E10. doi: 10.1038/s41586-022-04826-7
- 521 D'Antonio M, Nguyen JP, Arthur TD, Matsui H, Initiative C-HG, D'Antonio-Chronowska A, Frazer KA
 522 (2021) SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic
 523 variants affecting gene expression in a variety of tissues. Cell Rep 37: 110020. doi:
 524 10.1016/j.celrep.2021.110020
- 525 Davies NM, Holmes MV, Davey Smith G (2018) Reading Mendelian randomisation studies: a guide,
 526 glossary, and checklist for clinicians. BMJ 362: k601. doi: 10.1136/bmj.k601
- De Biasi S, Meschiari M, Gibellini L, Bellinazzi C, Borella R, Fidanza L, Gozzi L, Iannone A, Lo Tartaro
 D, Mattioli M, Paolini A, Menozzi M, Milic J, Franceschi G, Fantini R, Tonelli R, Sita M, Sarti
 M, Trenti T, Brugioni L, Cicchetti L, Facchinetti F, Pietrangelo A, Clini E, Girardis M, Guaraldi
 G, Mussini C, Cossarizza A (2020) Marked T cell activation, senescence, exhaustion and skewing
 towards TH17 in patients with COVID-19 pneumonia. Nat Commun 11: 3434. doi:
 10.1038/s41467-020-17292-4
- 533 Degenhardt F, Ellinghaus D, Juzenas S, Lerga-Jaso J, Wendorff M, Maya-Miles D, Uellendahl-Werth F, 534 ElAbd H, Ruhlemann MC, Arora J, Ozer O, Lenning OB, Myhre R, Vadla MS, Wacker EM, 535 Wienbrandt L, Blandino Ortiz A, de Salazar A, Garrido Chercoles A, Palom A, Ruiz A, Garcia-536 Fernandez AE, Blanco-Grau A, Mantovani A, Zanella A, Holten AR, Mayer A, Bandera A, 537 Cherubini A, Protti A, Aghemo A, Gerussi A, Ramirez A, Braun A, Nebel A, Barreira A, Lleo A, 538 Teles A, Kildal AB, Biondi A, Caballero-Garralda A, Ganna A, Gori A, Gluck A, Lind A, Tanck 539 A, Hinney A, Carreras Nolla A, Fracanzani AL, Peschuck A, Cavallero A, Dyrhol-Riise AM, 540 Ruello A, Julia A, Muscatello A, Pesenti A, Voza A, Rando-Segura A, Solier A, Schmidt A,
- 541 Cortes B, Mateos B, Nafria-Jimenez B, Schaefer B, Jensen B, Bellinghausen C, Maj C, Ferrando
- 542 C, de la Horra C, Quereda C, Skurk C, Thibeault C, Scollo C, Herr C, Spinner CD, Gassner C,
 543 Lange C, Hu C, Paccapelo C, Lehmann C, Angelini C, Cappadona C, Azuure C, Covicat study
- group AS, Bianco C, Cea C, Sancho C, Hoff DAL, Galimberti D, Prati D, Haschka D, Jimenez D,
 Pestana D, Toapanta D, Muniz-Diaz E, Azzolini E, Sandoval E, Binatti E, Scarpini E, Helbig ET,
 et al. (2022) Detailed stratified GWAS analysis for severe COVID-19 in four European
 populations. Hum Mol Genet 31: 3945-3966. doi: 10.1093/hmg/ddac158
- Forgetta V, Jiang L, Vulpescu NA, Hogan MS, Chen S, Morris JA, Grinek S, Benner C, Jang DK, Hoang
 Q, Burtt N, Flannick JA, McCarthy MI, Fauman E, Greenwood CMT, Maurano MT, Richards JB
 (2022) An effector index to predict target genes at GWAS loci. Hum Genet. doi: 10.1007/s00439022-02434-z
- Fricke-Galindo I, Martinez-Morales A, Chavez-Galan L, Ocana-Guzman R, Buendia-Roldan I, Perez-Rubio G, Hernandez-Zenteno RJ, Veronica-Aguilar A, Alarcon-Dionet A, Aguilar-Duran H, Gutierrez-Perez IA, Zaragoza-Garcia O, Alanis-Ponce J, Camarena A, Bautista-Becerril B, Nava-Quiroz KJ, Mejia M, Guzman-Guzman IP, Falfan-Valencia R (2022) IFNAR2 relevance in the clinical outcome of individuals with severe COVID-19. Front Immunol 13: 949413. doi: 10.3389/fimmu.2022.949413
- Gaziano L, Giambartolomei C, Pereira AC, Gaulton A, Posner DC, Swanson SA, Ho YL, Iyengar SK,
 Kosik NM, Vujkovic M, Gagnon DR, Bento AP, Barrio-Hernandez I, Ronnblom L, Hagberg N,
 Lundtoft C, Langenberg C, Pietzner M, Valentine D, Gustincich S, Tartaglia GG, Allara E,
 Surendran P, Burgess S, Zhao JH, Peters JE, Prins BP, Angelantonio ED, Devineni P, Shi Y,
 Lynch KE, DuVall SL, Garcon H, Thomann LO, Zhou JJ, Gorman BR, Huffman JE, O'Donnell

Colocalization of expression transcripts with COVID-19 outcomes is dependent on cell-type and cell-state.

563 CJ, Tsao PS, Beckham JC, Pyarajan S, Muralidhar S, Huang GD, Ramoni R, Beltrao P, Danesh J, 564 Hung AM, Chang KM, Sun YV, Joseph J, Leach AR, Edwards TL, Cho K, Gaziano JM, Butterworth AS, Casas JP, Initiative VAMVPC-S (2021) Actionable druggable genome-wide 565 566 Mendelian randomization identifies repurposing opportunities for COVID-19. Nat Med 27: 668-567 676. doi: 10.1038/s41591-021-01310-z 568 GTEx Consortium (2020) The GTEx Consortium atlas of genetic regulatory effects across human tissues. 569 Science 369: 1318-1330. doi: 10.1126/science.aaz1776 570 Hernandez Cordero AI, Li X, Milne S, Yang CX, Bosse Y, Joubert P, Timens W, van den Berge M, 571 Nickle D, Hao K, Sin DD (2021) Multi-omics highlights ABO plasma protein as a causal risk 572 factor for COVID-19. Hum Genet 140: 969-979. doi: 10.1007/s00439-021-02264-5 573 Kanai M, Elzur R, Zhou W, Global Biobank Meta-analysis I, Daly MJ, Finucane HK (2022) Meta-574 analysis fine-mapping is often miscalibrated at single-variant resolution. Cell Genom 2. doi: 575 10.1016/j.xgen.2022.100210 576 Kanai M, Ulirsch JC, Karjalainen J, Kurki M, Karczewski KJ, Fauman E, Wang OS, Jacobs H, Aguet F, 577 Ardlie KG, Kerimov N, Alasoo K, Benner C, Ishigaki K, Sakaue S, Reilly S, Kamatani Y, 578 Matsuda K, Palotie A, Neale BM, Tewhey R, Sabeti PC, Okada Y, Daly MJ, Finucane HK (2021) 579 Insights from complex trait fine-mapping across diverse populations. medRxiv. doi: 580 10.1101/2021.09.03.21262975 Kousathanas A, Pairo-Castineira E, Rawlik K, Stuckey A, Odhams CA, Walker S, Russell CD. 581 582 Malinauskas T, Wu Y, Millar J, Shen X, Elliott KS, Griffiths F, Oosthuyzen W, Morrice K, 583 Keating S, Wang B, Rhodes D, Klaric L, Zechner M, Parkinson N, Siddiq A, Goddard P, 584 Donovan S, Maslove D, Nichol A, Semple MG, Zainy T, Maleady-Crowe F, Todd L, Salehi S, 585 Knight J, Elgar G, Chan G, Arumugam P, Patch C, Rendon A, Bentley D, Kingsley C, Kosmicki 586 JA, Horowitz JE, Baras A, Abecasis GR, Ferreira MAR, Justice A, Mirshahi T, Oetjens M, Rader 587 DJ, Ritchie MD, Verma A, Fowler TA, Shankar-Hari M, Summers C, Hinds C, Horby P, Ling L, 588 McAuley D, Montgomery H, Openshaw PJM, Elliott P, Walsh T, Tenesa A, Gen Oi, andMe i, 589 Initiative C-HG, Fawkes A, Murphy L, Rowan K, Ponting CP, Vitart V, Wilson JF, Yang J, 590 Bretherick AD, Scott RH, Hendry SC, Moutsianas L, Law A, Caulfield MJ, Baillie JK (2022) 591 Whole-genome sequencing reveals host factors underlying critical COVID-19. Nature 607: 97-592 103. doi: 10.1038/s41586-022-04576-6 593 Krishnamoorthy S, Li GH, Cheung CL (2023) Transcriptome-wide summary data-based Mendelian 594 randomization analysis reveals 38 novel genes associated with severe COVID-19. J Med Virol 595 95: e28162. doi: 10.1002/jmv.28162 596 Kundu R, Narean JS, Wang L, Fenn J, Pillay T, Fernandez ND, Conibear E, Koycheva A, Davies M, 597 Tolosa-Wright M, Hakki S, Varro R, McDermott E, Hammett S, Cutajar J, Thwaites RS, Parker 598 E, Rosadas C, McClure M, Tedder R, Taylor GP, Dunning J, Lalvani A (2022) Cross-reactive 599 memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. 600 Nat Commun 13: 80. doi: 10.1038/s41467-021-27674-x 601 Lamontagne M, Berube JC, Obeidat M, Cho MH, Hobbs BD, Sakornsakolpat P, de Jong K, Boezen HM, 602 International CGC, Nickle D, Hao K, Timens W, van den Berge M, Joubert P, Laviolette M, Sin 603 DD, Pare PD, Bosse Y (2018) Leveraging lung tissue transcriptome to uncover candidate causal 604 genes in COPD genetic associations. Hum Mol Genet 27: 1819-1829. doi: 10.1093/hmg/ddy091 605 Li P, Ke Y, Shen W, Shi S, Wang Y, Lin K, Guo X, Wang C, Zhang Y, Zhao Z (2022) Targeted 606 screening of genetic associations with COVID-19 susceptibility and severity. Front Genet 13: 607 1073880. doi: 10.3389/fgene.2022.1073880 608 Liu D, Yang J, Feng B, Lu W, Zhao C, Li L (2021) Mendelian randomization analysis identified genes 609 pleiotropically associated with the risk and prognosis of COVID-19. J Infect 82: 126-132. doi: 610 10.1016/j.jinf.2020.11.031 611 Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, Wu JE, Alanio C, Kuri-Cervantes L, 612 Pampena MB, D'Andrea K, Manne S, Chen Z, Huang YJ, Reilly JP, Weisman AR, Ittner CAG, 613 Kuthuru O, Dougherty J, Nzingha K, Han N, Kim J, Pattekar A, Goodwin EC, Anderson EM,

614	Weirick ME, Gouma S, Arevalo CP, Bolton MJ, Chen F, Lacey SF, Ramage H, Cherry S,
615	Hensley SE, Apostolidis SA, Huang AC, Vella LA, Unit UPCP, Betts MR, Meyer NJ, Wherry EJ
616	(2020) Deep immune profiling of COVID-19 patients reveals distinct immunotypes with
617	therapeutic implications. Science 369. doi: 10.1126/science.abc8511
618	Mehandru S, Merad M (2022) Pathological sequelae of long-haul COVID. Nat Immunol 23: 194-202.
619	doi: 10.1038/s41590-021-01104-y
620	Merad M, Blish CA, Sallusto F, Iwasaki A (2022) The immunology and immunopathology of COVID-
621	19. Science 375: 1122-1127. doi: 10.1126/science.abm8108
622	Nakanishi T, Farjoun Y, Willett J, Allen RJ, Guillen-Guio B, Zhou S, Richards JB (2022) Alternative
623	splicing in the lung influences COVID-19 severity and respiratory diseases. medRxiv. doi:
624	10.1101/2022.10.18.22281202
625	Ong EZ, Chan YFZ, Leong WY, Lee NMY, Kalimuddin S, Haja Mohideen SM, Chan KS, Tan AT,
626	Bertoletti A, Ooi EE, Low JGH (2020) A Dynamic Immune Response Shapes COVID-19
627	Progression. Cell Host Microbe 27: 879-882 e2. doi: 10.1016/j.chom.2020.03.021
628	Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, Walker S, Parkinson N,
629	Fourman MH, Russell CD, Furniss J, Richmond A, Gountouna E, Wrobel N, Harrison D, Wang
630	B, Wu Y, Meynert A, Griffiths F, Oosthuyzen W, Kousathanas A, Moutsianas L, Yang Z, Zhai R,
631	Zheng C, Grimes G, Beale R, Millar J, Shih B, Keating S, Zechner M, Haley C, Porteous DJ,
632	Hayward C, Yang J, Knight J, Summers C, Shankar-Hari M, Klenerman P, Turtle L, Ho A,
633	Moore SC, Hinds C, Horby P, Nichol A, Maslove D, Ling L, McAuley D, Montgomery H, Walsh
634	T, Pereira AC, Renieri A, Gen OI, Investigators IC, Initiative C-HG, andMe I, Investigators B,
635	Gen CI, Shen X, Ponting CP, Fawkes A, Tenesa A, Caulfield M, Scott R, Rowan K, Murphy L,
636	Openshaw PJM, Semple MG, Law A, Vitart V, Wilson JF, Baillie JK (2021) Genetic
637	mechanisms of critical illness in COVID-19. Nature 591: 92-98. doi: 10.1038/s41586-020-03065-
638	
639	y Daire Castingire E. Dowlik K. Klorig I. Kousethange A. Dichmond A. Miller I. Dussell CD. Malineuskas
640	Pairo-Castineira E, Rawlik K, Klaric L, Kousathanas A, Richmond A, Millar J, Russell CD, Malinauskas
641	T, Thwaites R, Stuckey A, Odhams CA, Walker S, Griffiths F, Oosthuyzen W, Morrice K, Keating S, Nichol A, Semple MG, Knight J, Shankar-Hari M, Summers C, Hinds C, Horby P,
642	
643	Ling L, McAuley D, Montgomery H, Openshaw PJM, Walsh T, Tenesa A, Scott RH, Caulfield MJ, Moutsianas L, Ponting CP, Wilson JF, Vitart V, Pereira AC, Luchessi A, Parra E, Cruz-
644 644	Guerrero R, Carracedo A, Fawkes A, Murphy L, Rowan K, Law A, Hendry SC, Baillie JK (2022)
645	GWAS and meta-analysis identifies multiple new genetic mechanisms underlying severe Covid-
646	19. medRxiv. doi: 10.1101/2022.03.07.22271833
647	Pietzner M, Chua RL, Wheeler E, Jechow K, Willett JDS, Radbruch H, Trump S, Heidecker B, Zeberg H,
648	
649	Heppner FL, Eils R, Mall MA, Richards JB, Sander LE, Lehmann I, Lukassen S, Wareham NJ, Conrad C, Langenberg C (2022) ELF5 is a potential respiratory epithelial cell-specific risk gene
650	for severe COVID-19. Nat Commun 13: 4484. doi: 10.1038/s41467-022-31999-6
651	Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, Boehnke M, Abecasis GR, Willer
652	CJ (2010) LocusZoom: regional visualization of genome-wide association scan results.
653	Bioinformatics 26: 2336-7. doi: 10.1093/bioinformatics/btq419
654	Randolph HE, Fiege JK, Thielen BK, Mickelson CK, Shiratori M, Barroso-Batista J, Langlois RA,
655 655	Barreiro LB (2021) Genetic ancestry effects on the response to viral infection are pervasive but
656	cell type specific. Science 374: 1127-1133. doi: 10.1126/science.abg0928
657	Rocheleau G, Forrest IS, Duffy A, Bafna S, Dobbyn A, Verbanck M, Won HH, Jordan DM, Do R (2022)
658	A tissue-level phenome-wide network map of colocalized genes and phenotypes in the UK
659	Biobank. Commun Biol 5: 849. doi: 10.1038/s42003-022-03820-z
660	Schmiedel BJ, Rocha J, Gonzalez-Colin C, Bhattacharyya S, Madrigal A, Ottensmeier CH, Ay F,
661	Chandra V, Vijayanand P (2021) COVID-19 genetic risk variants are associated with expression
662	of multiple genes in diverse immune cell types. Nat Commun 12: 6760. doi: 10.1038/s41467-
663	021-26888-3
000	021-20000 ⁻ J

 Greinomewia Association Study of Severe Covid-19 with Respiratory Falure. N Engl J Med 385: 1522-1534. doi: 10.1056/NEJMoa202028 Sharif-Zak M, Abbasi-Jorjandi M, Asadikaram G, Ghoreshi ZA, Rezazadeh-Jabalbarzi M, Afsharipur A, Rashidinejad H, Khajepour F, Jafarzadeh A, Arefinia N, Kheyrkhah A, Abolhassani M (2022) CCR2 and DPP9 expression in the peripheral blood of COVID-19 patients: Influences of the disease severity and gender. Immunobiology 227: 152184. doi: 10.1016/j.imbio.2022.152184 Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB (2021) Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA 326: 1614-1621. doi: 10.1001/jama.2021.18236 Smith GD, Ebrahim S (2003) 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32: 1-22. doi: 10.1093/ije/dy070 Soskic B, Cano-Gamez E, Smyth DJ, Ambridge K, Ke Z, Matte JC, Bossini-Castillo L, Kaplanis J, Ramirez-Navarro L, Lorenc A, Nakic N, Esparza-Gordillo J, Rowan W, Wille D, Tough DF, Bronson PG, Trynk G (2022) Immune disease risk variants regulate gene expression dynamics during CD4(+) T cell activation. Nat Genet. doi: 10.1038/s41588-022-01066-3 Tan LY, Komarasamy TV, Rnt Balasubramaniam V (2021) Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Front Immunol 12: 742941. doi: 10.3389/fimmu.2021.742941 Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K, Tombleson P, Comeau ME, Langefeld CD, Cunninghame Graham DS, Morris DL, Vyse TJ (2022) COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.100253 Wu L,	664 665 667 668 669 670 671 672 673 674 675 676 677 677	 Severe Covid GG, Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, Fernandez J, Prati D, Baselli G, Asselta R, Grimsrud MM, Milani C, Aziz F, Kassens J, May S, Wendorff M, Wienbrandt L, Uellendahl-Werth F, Zheng T, Yi X, de Pablo R, Chercoles AG, Palom A, Garcia-Fernandez AE, Rodriguez-Frias F, Zanella A, Bandera A, Protti A, Aghemo A, Lleo A, Biondi A, Caballero-Garralda A, Gori A, Tanck A, Carreras Nolla A, Latiano A, Fracanzani AL, Peschuck A, Julia A, Pesenti A, Voza A, Jimenez D, Mateos B, Nafria Jimenez B, Quereda C, Paccapelo C, Gassner C, Angelini C, Cea C, Solier A, Pestana D, Muniz-Diaz E, Sandoval E, Paraboschi EM, Navas E, Garcia Sanchez F, Ceriotti F, Martinelli-Boneschi F, Peyvandi F, Blasi F, Tellez L, Blanco-Grau A, Hemmrich-Stanisak G, Grasselli G, Costantino G, Cardamone G, Foti G, Aneli S, Kurihara H, ElAbd H, My I, Galvan-Femenia I, Martin J, Erdmann J, Ferrusquia-Acosta J, Garcia-Etxebarria K, Izquierdo-Sanchez L, Bettini LR, Sumoy L, Terranova L, Moreira L, Santoro L, Scudeller L, Mesonero F, Roade L, Ruhlemann MC, Schaefer M, Carrabba M, Riveiro-Barciela M, Figuera Basso ME, Valsecchi MG, Hernandez-Tejero M, Acosta-Herrera M, D'Angio M, Baldini M, Cazzaniga M, Schulzky M, Cecconi M, Wittig M, et al. (2020)
 Sharif-Zak M, Abbasi-Jorjandi M, Asadikaram G, Ghoreshi ZA, Rezazadeh-Jabalbarzi M, Afsharipur A, Rashidinejad H, Khajepour F, Jafarzadeh A, Arefinia N, Kheytkah A, Abolhassani M (2022) CCR2 and DP99 expression in the peripheral blood of COVID-19 patients: Influences of the disease severity and gender. Immunobiology 227: 152184. doi: 10.1016/j.imbio.2022.152184 Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB (2021) Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA 326: 1614-1621. doi: 10.1001/jama.2021.18236 Smith GD, Ebrahim S (2003) Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32: 1-22. doi: 10.1093/ije/dyg070 Soskic B, Cano-Gamez E, Smyth DJ, Ambridge K, Ke Z, Matte JC, Bossini-Castillo L, Kaplanis J, Ramirez-Navaro L, Lorenc A, Nakic N, Esparza-Gordillo J, Rowan W, Wille D, Tough DF, Bronson PG, Trynka G (2022) Immune disease risk variants regulate gene expression dynamics during CD4(+) T cell activation. Nat Genet. doi: 10.1038/s41588-022-01666-3 Tan LY, Komarasamy TV, Rmt Balasubramaniam V (2021) Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Front Immunol 12: 742941. doi: 10.3389/fimmu.2021.742941 Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K, Tombleson P, Comeau ME, Langefeld CD, Cunninghame Graham DS, Morris DL, Vyse TJ (2022) COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.1010253 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal genes for COVID-19 severity. Genet Med 23: 207	678 670	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med 383:
 Rashidinejad H, Khajepour F, Jafarzadeh A, Arefinia N, Kheyrkhah A, Abolhassani M (2022) CCR2 and DPP9 expression in the peripheral blood of COVID-19 patients: Influences of the disease severity and gender. Immunobiology 227: 152184. doi: 10.1016/j.imbio.2022.152184 Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB (2021) Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA 326: 1614-1621. doi: 10.1001/jama.2021.18236 Smith GD, Ebrahim S (2003) 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32: 1-22. doi: 10.1093/ije/dyg070 Soskic B, Cano-Gamez E, Smyth DJ, Ambridge K, Ke Z, Matte JC, Bossini-Castillo L, Kaplanis J, Ramirez-Navarro L, Lorenc A, Nakic N, Esparza-Gordillo J, Rowan W, Wille D, Tough DF, Bronson PG, Trynka G (2022) Immune disease risk variants regulate gene expression dynamics during CD4(+) T cell activation. Nat Genet. doi: 10.1038/s41588-022-01066-3 Tan LY, Komarasamy TV, Rmt Balasubramaniam V (2021) Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Front Immunol 12: 742941. doi: 10.3389/fimmu.2021.742941 Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K, Tombleson P, Comeau ME, Langefeld CD, Cunninghame Graham DS, Morris DL, Vyse TJ (2022) COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.1010253 Wu L, Zhu J, Liu D, Sun Y, Wu C (2		
 CCR2 and DPP9 expression in the peripheral blood of COVID-19 patients: Influences of the disease severity and gender. Immunobiology 227: 152184. doi: 10.1016/j.imbio.2022.152184 Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB (2021) Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA 326: 1614-1621. doi: 10.1001/jama.2021.18236 Smith GD, Ebrahim S (2003) 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32: 1-22. doi: 10.1093/ije/dyg070 Soskic B, Cano-Gamez E, Smyth DJ, Ambridge K, Ke Z, Matte JC, Bossini-Castillo L, Kaplanis J, Ramirez-Navarro L, Lorenc A, Nakic N, Esparza-Gordillo J, Rowan W, Wille D, Tough DF, Bronson PG, Trynka G (2022) Immune disease risk variants regulate gene expression dynamics during CD4(+) T cell activation. Nat Genet. doi: 10.1038/s41588-022-01066-3 Tan LY, Komarasamy TV, Rmt Balasubramaniam V (2021) Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Front Immunol 12: 742941. doi: 10.3389/fimmu.2021.742941 Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K, Tombleson P, Comeau ME, Langefeld CD, Cunninghame Graham DS, Morris DL, Vyse TJ (2022) COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.1010253 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal genes for COVID-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 Yoshiji S, Butter-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, Hultstrom M, Ilboudo Y, Afrasiabi		
 disease severity and gender. Immunobiology 227: 152184. doi: 10.1016/j.imbio.2022.152184 Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB (2021) Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA 326: 1614-1621. doi: 10.1001/jama.2021.18236 Smith GD, Ebrahim S (2003) 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32: 1-22. doi: 10.1093/ije/dyg070 Soskic B, Cano-Gamez E, Smyth DJ, Ambridge K, Ke Z, Matte JC, Bossini-Castillo L, Kaplanis J, Ramirez-Navarro L, Lorenc A, Nakic N, Esparza-Gordillo J, Rowan W, Wille D, Tough DF, Bronson PG, Trynka G (2022) Immune disease risk variants regulate gene expression dynamics during CD4(+) T cell activation. Nat Genet. doi: 10.1038/s41588-022-01066-3 Tan LY, Komarasamy TV, Rmt Balasubramaniam V (2021) Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Front Immunol 12: 742941. doi: 10.3389/fimmu.2021.742941 Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K, Tombleson P, Comeau ME, Langefeld CD, Cunninghame Graham DS, Morris DL, Vyse TJ (2022) COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.1010253 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal genes for COVID-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaezi M, Tselios C, Xue X, Bouab M, Shi F, Laurent L, Munt		
 Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB (2021) Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA 326: 1614-1621. doi: 10.1001/jama.2021.18236 Smith GD, Ebrahim S (2003) 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32: 1-22. doi: 10.1093/ije/dyg070 Soskic B, Cano-Gamez E, Smyth DJ, Ambridge K, Ke Z, Matte JC, Bossini-Castillo L, Kaplanis J, Ramirez-Navarro L, Lorenc A, Nakic N, Esparza-Gordillo J, Rowan W, Wille D, Tough DF, Bronson PG, Trynka G (2022) Immune disease risk variants regulate gene expression dynamics during CD4(+) T cell activation. Nat Genet. doi: 10.1038/s41588-022-01066-3 Tan LY, Komarasamy TV, Rmt Balasubramaniam V (2021) Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Front Immunol 12: 742941. doi: 10.3389/fimmu.2021.742941 Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K, Tombleson P, Comeau ME, Langefeld CD, Cunninghame Graham DS, Morris DL, Vyse TJ (2022) COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.1010253 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal genes for COVID-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaazi M, Tselios C, Xue X, Bouab M,		
 TJ, Higgins JPT, Timpson NJ, Dimou N, Langenberg C, Golub RM, Loder EW, Gallo V, Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB (2021) Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement, JAMA 326: 1614-1621. doi: 10.1001/jama.2021.18236 Smith GD, Ebrahim S (2003) 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32: 1-22. doi: 10.1093/ije/dyg070 Soskic B, Cano-Gamez E, Smyth DJ, Ambridge K, Ke Z, Matte JC, Bossini-Castillo L, Kaplanis J, Ramirez-Navarro L, Lorenc A, Nakic N, Esparza-Gordillo J, Rowan W, Wille D, Tough DF, Bronson PG, Trynka G (2022) Immune disease risk variants regulate gene expression dynamics during CD4(+) T cell activation. Nat Genet. doi: 10.1038/s41588-022-01066-3 Tan LY, Komarasamy TV, Rmt Balasubramaniam V (2021) Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Front Immunol 12: 742941. doi: 10.3389/fimmu.2021.742941 Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K, Tombleson P, Comeau ME, Langefeld CD, Cunninghame Graham DS, Morris DL, Vyse TJ (2022) COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.1010253 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal genes for COVID-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaazi M, Tselios C, Xue X, Bouab M, Shi F,		
 Tybjaerg-Hansen A, Davey Smith G, Egger M, Richards JB (2021) Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA 326: 1614-1621. doi: 10.1001/jama.2021.18236 Smith GD, Ebrahim S (2003) 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32: 1-22. doi: 10.1093/ije/dyg070 Soskic B, Cano-Gamez E, Smyth DJ, Ambridge K, Ke Z, Matte JC, Bossini-Castillo L, Kaplanis J, Ramirez-Navarro L, Lorenc A, Nakic N, Esparza-Gordillo J, Rowan W, Wille D, Tough DF, Bronson PG, Trynka G (2022) Immune disease risk variants regulate gene expression dynamics during CD4(+) T cell activation. Nat Genet. doi: 10.1038/s41588-022-01066-3 Tan LY, Komarasamy TV, Rmt Balasubramaniam V (2021) Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Front Immunol 12: 742941. doi: 10.3389/fimmu.2021.742941 Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K, Tombleson P, Comeau ME, Langefeld CD, Cunninghame Graham DS, Morris DL, Vyse TJ (2022) COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.gen.1010253 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal genes for COVID-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaezi M, Tselios C, Xue X, Bouab M, Shi F, Laurent L, Munter HM, Afilalo M, Afilalo J, Mooser V, Timpson NJ, Zeberg H, Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w<td></td><td></td>		
 Statement. JAMA 326: 1614-1621. doi: 10.1001/jama.2021.18236 Smith GD, Ebrahim S (2003) 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32: 1-22. doi: 10.1093/ije/dyg070 Soskic B, Cano-Gamez E, Smyth DJ, Ambridge K, Ke Z, Matte JC, Bossini-Castillo L, Kaplanis J, Ramirez-Navarro L, Lorenc A, Nakic N, Esparza-Gordillo J, Rowan W, Wille D, Tough DF, Bronson PG, Trynka G (2022) Immune disease risk variants regulate gene expression dynamics during CD4(+) T cell activation. Nat Genet. doi: 10.1038/s41588-022-01066-3 Tan LY, Komarasamy TV, Rmt Balasubramaniam V (2021) Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Front Immunol 12: 742941. doi: 10.3389/fimmu.2021.742941 Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K, Tombleson P, Comeau ME, Langefeld CD, Cunninghame Graham DS, Morris DL, Vyse TJ (2022) COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.1010253 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal genes for COVID-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaezi M, Tselios C, Xue X, Bouab M, Shi F, Laurent L, Munter HM, Afilalo M, Afilalo J, Mooser V, Timpson NJ, Zeberg H, Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB,	686	
 Smith GD, Ebrahim S (2003) 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32: 1-22. doi: 10.1093/ije/dyg070 Soskic B, Cano-Gamez E, Smyth DJ, Ambridge K, Ke Z, Matte JC, Bossini-Castillo L, Kaplanis J, Ramirez-Navarro L, Lorenc A, Nakic N, Espaza-Gordillo J, Rowan W, Wille D, Tough DF, Bronson PG, Trynka G (2022) Immune disease risk variants regulate gene expression dynamics during CD4(+) T cell activation. Nat Genet. doi: 10.1038/s41588-022-01066-3 Tan LY, Komarasamy TV, Rmt Balasubramaniam V (2021) Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Front Immunol 12: 742941. doi: 10.3389/fimmu.2021.742941 Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K, Tombleson P, Comeau ME, Langefeld CD, Cunnighame Graham DS, Morris DL, Vyse TJ (2022) COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.1010253 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal genes for COVID-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaezi M, Tselios C, Xue X, Bouab M, Shi F, Laurent L, Munter HM, Afilalo M, Afilalo J, Mooser V, Timpson NJ, Zeberg H, Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Ho	687	of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR
 understanding environmental determinants of disease? Int J Epidemiol 32: 1-22. doi: 10.1093/ije/dyg070 Soskic B, Cano-Gamez E, Smyth DJ, Ambridge K, Ke Z, Matte JC, Bossini-Castillo L, Kaplanis J, Ramirez-Navarro L, Lorenc A, Nakic N, Esparza-Gordillo J, Rowan W, Wille D, Tough DF, Bronson PG, Trynka G (2022) Immune disease risk variants regulate gene expression dynamics during CD4(+) T cell activation. Nat Genet. doi: 10.1038/s41588-022-01066-3 Tan LY, Komarasamy TV, Rmt Balasubramaniam V (2021) Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Front Immunol 12: 742941. doi: 10.3389/fimmu.2021.742941 Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K, Tombleson P, Comeau ME, Langefeld CD, Cunninghame Graham DS, Morris DL, Vyse TJ (2022) COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.1010253 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal genes for COVID-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaezi M, Tselios C, Xue X, Bouab M, Shi F, Laurent L, Munter HM, Afilalo M, Afilalo J, Mooser V, Timpson NJ, Zeberg H, Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 	688	Statement. JAMA 326: 1614-1621. doi: 10.1001/jama.2021.18236
 10.1093/ije/dyg070 Soskic B, Cano-Gamez E, Smyth DJ, Ambridge K, Ke Z, Matte JC, Bossini-Castillo L, Kaplanis J, Ramirez-Navarro L, Lorenc A, Nakic N, Esparza-Gordillo J, Rowan W, Wille D, Tough DF, Bronson PG, Trynka G (2022) Immune disease risk variants regulate gene expression dynamics during CD4(+) T cell activation. Nat Genet. doi: 10.1038/s41588-022-01066-3 Tan LY, Komarasamy TV, Rmt Balasubramaniam V (2021) Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Front Immunol 12: 742941. doi: 10.3389/fimmu.2021.742941 Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K, Tombleson P, Comeau ME, Langefeld CD, Cunninghame Graham DS, Morris DL, Vyse TJ (2022) COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.1010253 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal genes for COVIDI-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaezi M, Tselios C, Xue X, Bouab M, Shi F, Laurent L, Munter HM, Afilalo M, Afilalo J, Mooser V, Timpson NJ, Zeberg H, Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. Nat Metab 5: 248-264. doi: 10.1038/s4225-023-00742-w Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 	689	
 Soskic B, Cano-Gamez E, Smyth DJ, Ambridge K, Ke Z, Matte JC, Bossini-Castillo L, Kaplanis J, Ramirez-Navarro L, Lorenc A, Nakic N, Esparza-Gordillo J, Rowan W, Wille D, Tough DF, Bronson PG, Trynka G (2022) Immune disease risk variants regulate gene expression dynamics during CD4(+) T cell activation. Nat Genet. doi: 10.1038/s41588-022-01066-3 Tan LY, Komarasamy TV, Rmt Balasubramaniam V (2021) Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Front Immunol 12: 742941. doi: 10.3389/fimmu.2021.742941 Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K, Tombleson P, Comeau ME, Langefeld CD, Cunninghame Graham DS, Morris DL, Vyse TJ (2022) COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.1010253 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal genes for COVID-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaezi M, Tselios C, Xue X, Bouab M, Shi F, Laurent L, Munter HM, Afilalo M, Afilalo J, Mooser V, Timpson NJ, Zeberg H, Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 		
 Ramirez-Navarro L, Lorenc A, Nakic N, Esparza-Gordillo J, Rowan W, Wille D, Tough DF, Bronson PG, Trynka G (2022) Immune disease risk variants regulate gene expression dynamics during CD4(+) T cell activation. Nat Genet. doi: 10.1038/s41588-022-01066-3 Tan LY, Komarasamy TV, Rmt Balasubramaniam V (2021) Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Front Immunol 12: 742941. doi: 10.3389/fimmu.2021.742941 Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K, Tombleson P, Comeau ME, Langefeld CD, Cunninghame Graham DS, Morris DL, Vyse TJ (2022) COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.1010253 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal genes for COVID-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaezi M, Tselios C, Xue X, Bouab M, Shi F, Laurent L, Munter HM, Afilalo M, Afilalo J, Mooser V, Timpson NJ, Zeberg H, Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 		
 Bronson PG, Trynka G (2022) Immune disease risk variants regulate gene expression dynamics during CD4(+) T cell activation. Nat Genet. doi: 10.1038/s41588-022-01066-3 Tan LY, Komarasamy TV, Rmt Balasubramaniam V (2021) Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Front Immunol 12: 742941. doi: 10.3389/fimmu.2021.742941 Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K, Tombleson P, Comeau ME, Langefeld CD, Cunninghame Graham DS, Morris DL, Vyse TJ (2022) COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.1010253 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal genes for COVID-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaezi M, Tselios C, Xue X, Bouab M, Shi F, Laurent L, Munter HM, Afilalo M, Afilalo J, Mooser V, Timpson NJ, Zeberg H, Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 		
 during CD4(+) T cell activation. Nat Genet. doi: 10.1038/s41588-022-01066-3 Tan LY, Komarasamy TV, Rmt Balasubramaniam V (2021) Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Front Immunol 12: 742941. doi: 10.3389/fimmu.2021.742941 Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K, Tombleson P, Comeau ME, Langefeld CD, Cunninghame Graham DS, Morris DL, Vyse TJ (2022) COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.1010253 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal genes for COVID-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaezi M, Tselios C, Xue X, Bouab M, Shi F, Laurent L, Munter HM, Afilalo M, Afilalo J, Mooser V, Timpson NJ, Zeberg H, Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 		
 Tan LY, Komarasamy TV, Rmt Balasubramaniam V (2021) Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Front Immunol 12: 742941. doi: 10.3389/fimmu.2021.742941 Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K, Tombleson P, Comeau ME, Langefeld CD, Cunninghame Graham DS, Morris DL, Vyse TJ (2022) COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.1010253 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal genes for COVID-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaezi M, Tselios C, Xue X, Bouab M, Shi F, Laurent L, Munter HM, Afilalo M, Afilalo J, Mooser V, Timpson NJ, Zeberg H, Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 		
 697 COVID-19: A Double Edged Sword. Front Immunol 12: 742941. doi: 698 10.3389/fimmu.2021.742941 699 Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K, Tombleson P, Comeau ME, Langefeld CD, 700 Cunninghame Graham DS, Morris DL, Vyse TJ (2022) COVID-19 and systemic lupus 701 erythematosus genetics: A balance between autoimmune disease risk and protection against 702 infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.1010253 703 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal 704 genes for COVID-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 705 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, 706 Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaezi M, Tselios C, Xue X, 707 Bouab M, Shi F, Laurent L, Munter HM, Afilalo M, Afilalo J, Mooser V, Timpson NJ, Zeberg H, 708 Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization 709 implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. 710 Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w 711 Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, 712 Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, 713 Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 		
 10.3389/fimmu.2021.742941 Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K, Tombleson P, Comeau ME, Langefeld CD, Cunninghame Graham DS, Morris DL, Vyse TJ (2022) COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.1010253 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal genes for COVID-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaezi M, Tselios C, Xue X, Bouab M, Shi F, Laurent L, Munter HM, Afilalo M, Afilalo J, Mooser V, Timpson NJ, Zeberg H, Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 		
 Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K, Tombleson P, Comeau ME, Langefeld CD, Cunninghame Graham DS, Morris DL, Vyse TJ (2022) COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.1010253 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal genes for COVID-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaezi M, Tselios C, Xue X, Bouab M, Shi F, Laurent L, Munter HM, Afilalo M, Afilalo J, Mooser V, Timpson NJ, Zeberg H, Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 		
 Cunninghame Graham DS, Morris DL, Vyse TJ (2022) COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.1010253 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal genes for COVID-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaezi M, Tselios C, Xue X, Bouab M, Shi F, Laurent L, Munter HM, Afilalo M, Afilalo J, Mooser V, Timpson NJ, Zeberg H, Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 		
 rot erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.1010253 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal genes for COVID-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaezi M, Tselios C, Xue X, Bouab M, Shi F, Laurent L, Munter HM, Afilalo M, Afilalo J, Mooser V, Timpson NJ, Zeberg H, Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 		
 infection. PLoS Genet 18: e1010253. doi: 10.1371/journal.pgen.1010253 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal genes for COVID-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaezi M, Tselios C, Xue X, Bouab M, Shi F, Laurent L, Munter HM, Afilalo M, Afilalo J, Mooser V, Timpson NJ, Zeberg H, Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 		
 Wu L, Zhu J, Liu D, Sun Y, Wu C (2021) An integrative multiomics analysis identifies putative causal genes for COVID-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaezi M, Tselios C, Xue X, Bouab M, Shi F, Laurent L, Munter HM, Afilalo M, Afilalo J, Mooser V, Timpson NJ, Zeberg H, Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 		
 704 genes for COVID-19 severity. Genet Med 23: 2076-2086. doi: 10.1038/s41436-021-01243-5 705 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, 706 Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaezi M, Tselios C, Xue X, 707 Bouab M, Shi F, Laurent L, Munter HM, Afilalo M, Afilalo J, Mooser V, Timpson NJ, Zeberg H, 708 Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization 709 implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. 710 Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w 711 Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, 712 Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, 713 Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 		
 Yoshiji S, Butler-Laporte G, Lu T, Willett JDS, Su CY, Nakanishi T, Morrison DR, Chen Y, Liang K, Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaezi M, Tselios C, Xue X, Bouab M, Shi F, Laurent L, Munter HM, Afilalo M, Afilalo J, Mooser V, Timpson NJ, Zeberg H, Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 		
 Hultstrom M, Ilboudo Y, Afrasiabi Z, Lan S, Duggan N, DeLuca C, Vaezi M, Tselios C, Xue X, Bouab M, Shi F, Laurent L, Munter HM, Afilalo M, Afilalo J, Mooser V, Timpson NJ, Zeberg H, Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 		
 707 Bouab M, Shi F, Laurent L, Munter HM, Afilalo M, Afilalo J, Mooser V, Timpson NJ, Zeberg H, 708 Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization 709 implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. 710 Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w 711 Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, 712 Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, 713 Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 		
 implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 	707	
 710 Nat Metab 5: 248-264. doi: 10.1038/s42255-023-00742-w 711 Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, 712 Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, 713 Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 	708	Zhou S, Forgetta V, Farjoun Y, Richards JB (2023) Proteome-wide Mendelian randomization
 711 Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, Gutteridge A, Erola P, Liu Y, Luo S, 712 Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, 713 Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 		
 712 Robinson J, Richardson TG, Staley JR, Elsworth B, Burgess S, Sun BB, Danesh J, Runz H, 713 Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R, 		
713 Maranville JC, Martin HM, Yarmolinsky J, Laurin C, Holmes MV, Liu JZ, Estrada K, Santos R,		
		•
/14 McCarthy L, Waterworth D, Nelson MR, Smith GD, Butterworth AS, Hemani G, Scott RA,		
	714	McCarthy L, Waterworth D, Nelson MR, Smith GD, Butterworth AS, Hemani G, Scott RA,

715	Gaunt TR (2020) Phenome-wide Mendelian randomization mapping the influence of the plasma
716	proteome on complex diseases. Nat Genet 52: 1122-1131. doi: 10.1038/s41588-020-0682-6
717	Zhou S, Butler-Laporte G, Nakanishi T, Morrison DR, Afilalo J, Afilalo M, Laurent L, Pietzner M,
718	Kerrison N, Zhao K, Brunet-Ratnasingham E, Henry D, Kimchi N, Afrasiabi Z, Rezk N, Bouab
719	M, Petitjean L, Guzman C, Xue X, Tselios C, Vulesevic B, Adeleye O, Abdullah T, Almamlouk
720	N, Chen Y, Chasse M, Durand M, Paterson C, Normark J, Frithiof R, Lipcsey M, Hultstrom M,
721	Greenwood CMT, Zeberg H, Langenberg C, Thysell E, Pollak M, Mooser V, Forgetta V,
722	Kaufmann DE, Richards JB (2021) A Neanderthal OAS1 isoform protects individuals of
723	European ancestry against COVID-19 susceptibility and severity. Nat Med 27: 659-667. doi:
724	10.1038/s41591-021-01281-1
725	